Elicio Therapeutics, Inc. (NasdaqCM: ELTX)
Health Care · Biotechnology · US
$1.90
-2.06% today · -80.0% 1Y
Elicio Therapeutics, Inc. (NasdaqCM: ELTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $49.94M and employs 33 people.
Over the last twelve months the share price has lost 80.0%, trading between 1.44 and 16.00.
Tweenvest scores Elicio Therapeutics, Inc. across four factors: quality 36/100, value 24/100. Its strongest factor is quality.
ELTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $49.94M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.17
- Dividend yield
- —
- Beta (5Y)
- 1.98
- 52-week high
- $16.00
- 52-week low
- $1.44
- Avg volume (3M)
- —
- Shares outstanding
- 26.28M
- Employees
- 33
- Next earnings
- —
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
- ISIN
- US28657F1030
- Listed since
- Feb 5, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Cellid, Co., Ltd.KOSDAQ: A299660 | $50.90M | ₩2,300.00 | -8.18% |
| FluoGuide A/SOM: FLUO | $50.52M | Skr30.60 | -3.47% |
| Naturalendo Tech Co., Ltd.KOSDAQ: A168330 | $50.32M | ₩2,125.00 | -11.09% |
| Kidswell Bio CorporationTSE: 4584 | $50.31M | ¥157.00 | -1.88% |
| Arecor Therapeutics plcAIM: AREC | $49.86M | £0.83 | +13.79% |
| Alterity Therapeutics LimitedASX: ATH | $49.42M | AU$0.31 | -12.68% |
| iBio, Inc.NasdaqCM: IBIO | $49.28M | $0.77 | -12.02% |
| Adicet Bio, Inc.NasdaqCM: ACET | $49.19M | $4.57 | -18.54% |
Figures last refreshed Oct 18, 2026.